Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving survival. The dose and fractionation for adjuvant breast radiation therapy has evolved over time, as novel schedules have been compared to the current standard of care. Hypofractionated radiation therapy (266 cGy per fraction x 15-16 fractions over 3 weeks) has been shown to result in equivalent oncologic outcomes, as well as equivalent acute and late toxicity, when compar

Trial Details

NCT ID
NCT06559540
Phase
PHASE2
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Hypofractionated radiation
  • Ultra-hypofractionated breast/chest wall and regional nodal radiation
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Histologically confirmed invasive carcinoma of the breast. Metaplastic breast cancer is allowed.
  • AJCC 8th Edition Stage: cT1-3 primary tumor. cN1-2 or pN1-2.
  • Biopsy-proven involved axillary node(s) (either at baseline and/or at time of surgery).
  • Undergone either partial mastectomy (with negative final histologic margins (defined as no tumor on ink, after initial surgery or re-excision)) or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →